JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
US-Iran Ceasefire Under Pressure as Fresh Strait of Hormuz Clashes Shake Oil Markets 
China Export Growth Surges in April as Global Buyers Rush to Secure Supplies 
Oil Prices Surge as U.S.-Iran Conflict Threatens Strait of Hormuz Supply Route 
Saudi Aramco Q1 Profit Jumps 25% as Strait of Hormuz Crisis Reshapes Oil Exports 
Japan’s Yen Intervention and BOJ Rate Hike Bets Support Currency Recovery 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
European Stocks Edge Higher as Iran-U.S. Peace Talks Boost Market Sentiment 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Philips announced that it has started the repairs and replacements of its first-generation respiratory devices that were recalled in the United States. The healthcare unit of the Dutch multinational conglomerate will be addressing the issues in the recalled DreamStation devices numbering to millions.
Based on the recall notice, it was stated that the recalled machines pose potential health risks so customers were immediately told to stop using the affected model units of Philip’s respiratory machines. As Reuters reported, the U.S. Food and Drug Administration (FDA) announced a recall on some models of DreamStation respiratory and ventilator devices in June.
They were found to have become toxic over time as the foam part might deteriorate. When this happens, the machines may potentially cause cancer. Philips received authorization from the FDA to allow rework in the affected units that could reach four million in total.
Almost half of the affected respiratory machines were sold in the U.S. so the latest recall notification is for this country only at this time. For the rest of the world, Philips has issued a field safety notice for the issue which the FDA classified as Class I recall. In any case, the company said that it will take them about a year to replace or repair the machines.
“We fully recognize that the timeframe for remediation of the affected devices places patients in a difficult situation,” Royal Philips’ chief executive officer, Frans van Houten, said in a press release. “We are mobilized to deliver a solution to them as fast as possible. We have significantly increased our production, service and rework capacity, and further intensified our outreach to our customers and their patients.”
The CEO is also urging patients who are using the affected devices to register their units on the website dedicated for the recalls. This will help them with the process of tracking and obtaining details about the machines.
Aside from the ongoing repairs and replacements, Philips continues to communicate with the FDA to address any other details of the recall as well as mitigation plans in the country. The company has reserved $590 million for the recall operation this year.
